JP2026041886A5 - - Google Patents

Info

Publication number
JP2026041886A5
JP2026041886A5 JP2025230606A JP2025230606A JP2026041886A5 JP 2026041886 A5 JP2026041886 A5 JP 2026041886A5 JP 2025230606 A JP2025230606 A JP 2025230606A JP 2025230606 A JP2025230606 A JP 2025230606A JP 2026041886 A5 JP2026041886 A5 JP 2026041886A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
refamulin
prodrug
solvate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025230606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026041886A (ja
Filing date
Publication date
Priority claimed from JP2022562465A external-priority patent/JP2023522644A/ja
Application filed filed Critical
Publication of JP2026041886A publication Critical patent/JP2026041886A/ja
Publication of JP2026041886A5 publication Critical patent/JP2026041886A5/ja
Pending legal-status Critical Current

Links

JP2025230606A 2020-04-17 2025-12-04 プレウロムチリンの治療的使用 Pending JP2026041886A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063011474P 2020-04-17 2020-04-17
US63/011,474 2020-04-17
EP20170072 2020-04-17
EP20170072.1 2020-04-17
EP20183292 2020-06-30
EP20183292.0 2020-06-30
JP2022562465A JP2023522644A (ja) 2020-04-17 2021-04-16 プレウロムチリンの治療的使用
PCT/EP2021/025140 WO2021209174A1 (en) 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022562465A Division JP2023522644A (ja) 2020-04-17 2021-04-16 プレウロムチリンの治療的使用

Publications (2)

Publication Number Publication Date
JP2026041886A JP2026041886A (ja) 2026-03-10
JP2026041886A5 true JP2026041886A5 (enExample) 2026-05-19

Family

ID=75801547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562465A Pending JP2023522644A (ja) 2020-04-17 2021-04-16 プレウロムチリンの治療的使用
JP2025230606A Pending JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022562465A Pending JP2023522644A (ja) 2020-04-17 2021-04-16 プレウロムチリンの治療的使用

Country Status (9)

Country Link
US (1) US20230174472A1 (enExample)
EP (1) EP4135682A1 (enExample)
JP (2) JP2023522644A (enExample)
CN (1) CN115443131A (enExample)
BR (1) BR112022020007A2 (enExample)
CA (1) CA3180535A1 (enExample)
IL (1) IL297268A (enExample)
TW (1) TW202203908A (enExample)
WO (1) WO2021209174A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475834A1 (en) 2022-02-09 2024-12-18 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
CN119925362A (zh) * 2023-11-03 2025-05-06 阳光安津(南京)生物医药科技有限公司 一种化合物在制备用于治疗银屑病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
GB0803707D0 (en) 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103242210B (zh) 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
KR102656841B1 (ko) 2015-06-17 2024-04-12 나브리바 테라퓨틱스 게엠베하 레파뮬린의 주사가능한 약제학적 제형
CN110507823B (zh) * 2019-08-20 2021-08-24 中国医学科学院基础医学研究所 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用

Similar Documents

Publication Publication Date Title
KR100621281B1 (ko) 니메설라이드를 포함하는 방출제어형 조성물
US6433027B1 (en) Medicament compositions based on tiotropium bromide and formoterol fumarate
JP2007506775A5 (enExample)
JP2018517715A5 (enExample)
KR20070102659A (ko) 베타작용제의 이성체 및 항-콜린제를 포함하는 약제학적조성물
JP2020523335A5 (enExample)
EP2822560A1 (en) Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
JP2021525746A5 (enExample)
JP2023521887A5 (enExample)
JP2019529570A (ja) ミドドリンの組成物およびその使用方法
JP2021532193A5 (enExample)
KR20250040090A (ko) 액상 약제학적 조성물
KR101923403B1 (ko) 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물
KR20020050249A (ko) 포스포디에스테라제 4 억제제의 투여 방법
CA2827299A1 (en) Liquid propellant-free formulation comprising an antimuscarinic drug
JP2008533022A5 (enExample)
JP2023522644A (ja) プレウロムチリンの治療的使用
JP2024528731A (ja) 眼癌転移を予防するためのイブジラスト
CN105147703B (zh) 黄柏酮在制备防治溃疡性结肠炎的药物中的应用
KR20150002774A (ko) 아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
CN111991387A (zh) 去氢二异丁香酚在制备防治溃疡性结肠炎的药物中的应用
CN104983728B (zh) 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用
JP7527662B2 (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用
EP3820526B1 (en) Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
JP7224624B2 (ja) 顆粒及びその製造方法